Vaxess Technologies is a groundbreaking brand dedicated to improving global health. Their mission is to engineer more effective and accessible vaccines and therapeutics through innovative technology. At Vaxess, they believe in pushing the boundaries of conventional approaches and integrating diverse scientific disciplines to develop revolutionary solutions.

One of their remarkable innovations is the MIMIX™ therapy, a needle-free and virtually pain-free patch that resembles an adhesive bandage. Unlike traditional delivery methods, the MIMIX™ patch leverages the skin's active immune organ properties by employing silk protein tips loaded with slowly-releasing bioactive molecules. This unique approach ensures a gradual release of the therapeutic agents, mimicking the natural infection kinetics in the body.

What truly sets Vaxess apart is their pioneering use of silk proteins, combined with groundbreaking immune-activating biology. By harnessing the remarkable qualities of silk biomaterials, originally conceived at MIT and Tufts University, Vaxess creates highly adaptive and effective therapies that interact with the body in unprecedented ways. With Vaxess Technologies, the future of pharmaceutical delivery is being reimagined, making it more effective, accessible, and patient-friendly for improved human health worldwide